Atorvastastin and HIV associated immune activation

Use of Atorvastatin among HAART-treated adults with suboptimal immune recovery in Uganda

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201301000445375

Enrollment

Registered

2012-10-26

Start date

2012-12-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS Nutritional, Metabolic, Endocrine

Interventions

Atorvastatin group

Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 18years and above HAART for at least 4 years Sustained viral suppression CD4 increase below 300 (from the baseline)

Exclusion criteria

Exclusion criteria: History of opportunistic infection in the previous 6 months Pregnancy

Design outcomes

Primary

Measure	Time frame
25% reduction in immune activation levels using flowcytometry	—

Countries

Uganda

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026